This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pavelic, Z. P. Articles by Preisler, H. D. Search for Related Content PubMed PubMed Citation Articles by Pavelic, Z. P. Articles by Preisler, H. D.

c-myc, c-erbB-2, and Ki-67 Expression in Normal Breast Tissue and in Invasive and Noninvasive Breast Carcinoma¹

Departments of Otolaryngology-Head and Neck Surgery [Z. P. P., L. P., M. G., S. G.] and Internal Medicine [E. E. L., H. D. P.], College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0528, and Molecular Oncology, Inc., Gaithersburg, Maryland 20878 [E. A. B.]

c-myc, c-erbB-2, and Ki-67 expression was examined by immunohistochemistry in 11 normal breast tissues and 42 invasive and 14 noninvasive breast carcinomas. The c-myc product was detected in all breast carcinoma specimens and in 7 of 11 normal breast tissues. Invasive tumors stained more frequently with the anti-myc monoclonal antibody than did noninvasive tumors, while the level of expression in normal breast tissue was much less than that in breast cancer. Membrane staining of the c-erbB-2 protein was demonstrated in 29% (4 of 14) of noninvasive ductal carcinomas and in 45% (19 of 42) of invasive breast carcinomas. None of the 11 normal breast tissue samples was positive. The mean value of Ki-67-positive cells was 0.91 ± 0.31% for normal breast tissue, 4.57 ± 1.36% for noninvasive ductal carcinoma, and 12.76 ± 2.18% for invasive breast cancer. In 42 invasive breast carcinomas, the expression of c-myc, c-erbB-2, and Ki-67 proliferation marker were compared with lymph node status, estrogen receptor status, progesterone receptor status, and age of patients at diagnosis. c-erbB-2 overexpression and Ki-67 overexpression were identified as the only factors associated with lymph node status. We concluded that they might be additional prognostic factors for breast carcinoma.

¹ This work was supported in part by a grant from NIH (CA 41285), a grant from the American Cancer Society, and a University Research Council grant from the University of Cincinnati. Part of this paper was presented at the 1990 Annual Meeting of the American Association for Cancer Research, Washington, DC.

² To whom requests for reprints should be addressed, at the Department of Otolaryngology-Head and Neck Surgery, College of Medicine, University of Cincinnati, 231 Bethesda Avenue, Cincinnati, OH 45267-0528.

Received 8/ 7/90. Accepted 2/26/92.

This article has been cited by other articles:

				D. Bhandare, R. Nayar, M. Bryk, N. Hou, R. Cohn, N. Golewale, N. P. Parker, R. T. Chatterton, A. Rademaker, and S. A. Khan Endocrine Biomarkers in Ductal Lavage Samples from Women at High Risk for Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2620 - 2627. [Abstract] [Full Text] [PDF]

				B.-C. Lee, T.-H. Lee, R. Zagozdzon, S. Avraham, A. Usheva, and H. K. Avraham Carboxyl-Terminal Src Kinase Homologous Kinase Negatively Regulates the Chemokine Receptor CXCR4 through YY1 and Impairs CXCR4/CXCL12 (SDF-1{alpha})-Mediated Breast Cancer Cell Migration Cancer Res., April 1, 2005; 65(7): 2840 - 2845. [Abstract] [Full Text] [PDF]

				S. N. Lauber, S. Ali, and N. J. Gooderham The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity Carcinogenesis, December 1, 2004; 25(12): 2509 - 2517. [Abstract] [Full Text] [PDF]

				A. Hoque, N. Sneige, A. A. Sahin, D. G. Menter, J. W. Bacus, G. N. Hortobagyi, and S. M. Lippman HER-2/neu Gene Amplification in Ductal Carcinoma In Situ of the Breast Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 587 - 590. [Abstract] [Full Text] [PDF]

				K. C. Chan, W. F. Knox, J. M. Gee, J. Morris, R. I. Nicholson, C. S. Potten, and N. J. Bundred Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition on Epithelial Proliferation in Normal and Premalignant Breast Cancer Res., January 1, 2002; 62(1): 122 - 128. [Abstract] [Full Text] [PDF]

				K. Stoeber, T. D. Tlsty, L. Happerfield, G. A. Thomas, S. Romanov, L. Bobrow, E. D. Williams, and G. H. Williams DNA replication licensing and human cell proliferation J. Cell Sci., January 6, 2001; 114(11): 2027 - 2041. [Abstract] [Full Text] [PDF]

				A. Pich, E. Margaria, and L. Chiusa Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival J. Clin. Oncol., August 16, 2000; 18(16): 2948 - 2956. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, C. M. Zalles, J. R. Klemp, S. Kamel, S. Zeiger, and M. S. Mayo Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model J Natl Cancer Inst, August 2, 2000; 92(15): 1217 - 1227. [Abstract] [Full Text] [PDF]

				L. F. Barr, S. E. Campbell, G. B. Diette, E. W. Gabrielson, S. Kim, H. Shim, and C. V. Dang c-Myc Suppresses the Tumorigenicity of Lung Cancer Cells and Down-Regulates Vascular Endothelial Growth Factor Expression Cancer Res., January 1, 2000; 60(1): 143 - 149. [Abstract] [Full Text]

				I. Bieche, I. Laurendeau, S. Tozlu, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaud Quantitation of MYC Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-PCR Assay Cancer Res., June 1, 1999; 59(12): 2759 - 2765. [Abstract] [Full Text] [PDF]